Skip Nav Destination
Issues
1 November 2006
-
Cover Image
Cover Image
Array-based CGH identifies multiple genomic alterations in MSI-H and MSS colorectal tumors. A small, previously uncharacterized deletion at 16p13.2 was found in 35% of MSI-H and 21% of MSS tumors. Figure shows homozygous deletion of this region by dual-color FISH. Nuclei (blue) show two signals for 16 centromere (green) and the absence of signals for a BAC at 16p13.2 (labeled in red). FISH to an adjacent BAC control showed two red signals. For further details, please see Trautmann et al. on page 6379 of this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Editorial
The Biology Behind
Molecular Pathways
Human Cancer Biology
Activation of Hypoxia-Inducible Factor-1α Is Necessary for Lysophosphatidic Acid–Induced Vascular Endothelial Growth Factor Expression
Jangsoon Lee; Soon Young Park; Eun Kyung Lee; Chang Gyo Park; Hyun Cheol Chung; Sun Young Rha; Yong Kee Kim; Gyu-Un Bae; Bum Kyeong Kim; Jeung-Whan Han; Hoi Young Lee
Distribution of GPR30, a Seven Membrane–Spanning Estrogen Receptor, in Primary Breast Cancer and its Association with Clinicopathologic Determinants of Tumor Progression
Edward J. Filardo; Carl T. Graeber; Jeffrey A. Quinn; Murray B. Resnick; Dilip Giri; Ronald A. DeLellis; Margaret M. Steinhoff; Edmond Sabo
Imaging, Diagnosis, Prognosis
CA IX is an Independent Prognostic Marker in Premenopausal Breast Cancer Patients with One to Three Positive Lymph Nodes and a Putative Marker of Radiation Resistance
Donal J. Brennan; Karin Jirstrom; Åsa Kronblad; Robert C. Millikan; Goran Landberg; Michael J. Duffy; Lisa Rydén; William M. Gallagher; Sallyann L. O'Brien
Prognostic Value of Apoptosis in Rectal Cancer Patients of the Dutch Total Mesorectal Excision Trial: Radiotherapy Is Redundant in Intrinsically High-Apoptotic Tumors
Elza C. de Bruin; Cornelis J.H. van de Velde; Simone van de Pas; Iris D. Nagtegaal; J. Han J.M. van Krieken; Marleen J.E.M. Gosens; Lucy T.C. Peltenburg; Jan Paul Medema; Corrie A.M. Marijnen
Peroxisome Proliferator-Activated Receptor γ Is Highly Expressed in Pancreatic Cancer and Is Associated With Shorter Overall Survival Times
Glen Kristiansen; Juliane Jacob; Ann-Christin Buckendahl; Robert Grützmann; Ingo Alldinger; Bence Sipos; Günter Klöppel; Marcus Bahra; Jan M. Langrehr; Peter Neuhaus; Manfred Dietel; Christian Pilarsky
Variants of the hK2 Protein Gene (KLK2) Are Associated with Serum hK2 Levels and Predict the Presence of Prostate Cancer at Biopsy
Robert K. Nam; William W. Zhang; Laurence H. Klotz; John Trachtenberg; Michael A.S. Jewett; Joan Sweet; Ants Toi; Seamus Teahan; Vasundara Venkateswaran; Linda Sugar; Andrew Loblaw; Kathy Siminovitch; Steven A. Narod
Cancer Therapy: Clinical
Long-term Events in Adult Patients with Clinical Stage IA-IIA Nonbulky Hodgkin's Lymphoma Treated with Four Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Adjuvant Radiotherapy: A Single-Institution 15-Year Follow-up
Ercole Brusamolino; Ambrogia Baio; Ester Orlandi; Luca Arcaini; Francesco Passamonti; Vassiliki Griva; William Casagrande; Cristiana Pascutto; Pietro Franchini; Mario Lazzarino
Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors
Marissa N. Balak; Yixuan Gong; Gregory J. Riely; Romel Somwar; Allan R. Li; Maureen F. Zakowski; Anne Chiang; Guangli Yang; Ouathek Ouerfelli; Mark G. Kris; Marc Ladanyi; Vincent A. Miller; William Pao
A Phase I Study of Single Administration of Antibody-Directed Enzyme Prodrug Therapy with the Recombinant Anti–Carcinoembryonic Antigen Antibody-Enzyme Fusion Protein MFECP1 and a Bis-Iodo Phenol Mustard Prodrug
Astrid Mayer; Roslyn J. Francis; Surinder K. Sharma; Berend Tolner; Caroline J. Springer; Jan Martin; Geoff M. Boxer; James Bell; Alan J. Green; John A. Hartley; Clare Cruickshank; Julie Wren; Kerry A. Chester; Richard H.J. Begent
Cancer Therapy: Preclinical
Antileukemic Activity of Lysophosphatidic Acid Acyltransferase-β Inhibitor CT32228 in Chronic Myelogenous Leukemia Sensitive and Resistant to Imatinib
Paul La Rosée; Taiping Jia; Shadmer Demehri; Nicolai Härtel; Peter de Vries; Lynn Bonham; David Hollenback; Jack W. Singer; Junia V. Melo; Brian J. Druker; Michael W. Deininger
Schedule-Dependent Synergy between the Heat Shock Protein 90 Inhibitor 17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin and Doxorubicin Restores Apoptosis to p53-Mutant Lymphoma Cell Lines
Ana I. Robles; Mollie H. Wright; Bheru Gandhi; Steven S. Feis; Christin L. Hanigan; Adrian Wiestner; Lyuba Varticovski
Hedgehog: an Attribute to Tumor Regrowth after Chemoradiotherapy and a Target to Improve Radiation Response
Jennifer Sims-Mourtada; Julie G. Izzo; Smith Apisarnthanarax; Tsung-Teh Wu; Usha Malhotra; Rajyalashmi Luthra; Zhongxing Liao; Ritsuko Komaki; Albert van der Kogel; Jaffer Ajani; K.S. Clifford Chao
Anti-Vascular Endothelial Growth Factor Receptor-1 Antagonist Antibody as a Therapeutic Agent for Cancer
Yan Wu; Zhaojing Zhong; James Huber; Rajiv Bassi; Bridget Finnerty; Erik Corcoran; Huiling Li; Elizabeth Navarro; Paul Balderes; Xenia Jimenez; Henry Koo; Venkata R.M. Mangalampalli; Dale L. Ludwig; James R. Tonra; Daniel J. Hicklin
Cancer Susceptibility and Prevention
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds